SRSainath Raman

Sainath Raman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sainath Raman has a total of 255 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of implementing a mindfulness-based program for paediatric intensive care unit staff

    by Rahul S. Joshi, Gayatri Marwah, Sainath Raman, Kristen Jones, Connie Cai Ru Gan, Janine Hockley

  • Corticosteroid use in children with community acquired sepsis: a multicentre prospective cohort study

    by Elliot Long, Gregory J G Nolan, Amanda Williams, Shefali Jani, Simon Craig, Amit Kochar, Meredith Louise Borland, Natalie Phillips, Shane George, Stuart Dalziel, et al.

    Objectives: Corticosteroids in paediatric sepsis have the potential to improve outcomes, yet there is little supporting evidence regarding efficacy, choice of agents, dose or timing of administration. We describe the patterns of corticosteroid use in children hospitalised with suspected community-acquired sepsis. Design: This observational study used data from the multicentre multicountry Sepsis Epidemiology in Australian and New Zealand Emergency Departments study, collected from 2021 to 2023. Patients: Participants were children aged 0 to <18 years with suspected sepsis admitted to the hospital through 11 emergency departments in Australia and New Zealand. Main outcome measures: We report agent, dose and factors associated with administration for any corticosteroid administered within the first 24 hours of hospitalisation. Results: 5119 children had suspected sepsis with a median age of 1.6 years and in-hospital mortality of 1.0% (52/5119). The Phoenix sepsis criteria were met by 4.9% (252/5119) with mortality of 12.7% (32/252). Corticosteroids were used in 9.6% (489/5119) children overall and in 31.3% (79/252) meeting Phoenix sepsis criteria. The most commonly used corticosteroid was dexamethasone (69.5%, 340/489), followed by hydrocortisone (25.4%, 124/489) with considerable variation in preferences overall and between study sites. Factors that were associated with corticosteroid use were: older age, more than one comorbidity, elevated initial lactate, large volume fluid resuscitation and any vasopressor use. Conclusions: Children with suspected community acquired sepsis frequently received treatment with corticosteroids. Dexamethasone and hydrocortisone were the most used agents, with the vast majority used outside of the setting of fluid or catecholamine-refractory shock. Trial registration number: ACTRN12621000920897.

  • Secondary analysis of the 2021–2023 Sepsis Epidemiology in Australian and New Zealand Children Observational Dataset: Association Between Presenting Venous Lactate Concentration and 72-Hour Outcomes

    by Elliot Long, Stephen Hearps, Warwick Butt, Tom Rozen, James Williams, Amanda Williams, Ben Gelbart, Sarah McNab, Meredith L. Borland, Jarrod Cross, et al.

    Objectives: In pediatric patients with sepsis, we hypothesized that the initial venous lactate concentration would be associated with subsequent need for extracorporeal life support (ECLS) or death within 72 hours. Design: A planned secondary analysis of data from the multicenter, two-country Sepsis Epidemiology Emergency Departments (SENTINEL) study, collected 2021–2023. Setting: Acute care hospitals in Australia and New Zealand. Patients: SENTINEL participants were children of 0 to less than 18 years with suspected sepsis admitted to the hospital through 11 emergency departments. Interventions: None. Measurements and Main Results: We used the initial venous lactate concentration (sampling within 4 hr of hospital arrival) as an explanatory variable for subsequent need for ECLS or death within 72 hours. In 4806 children, with a median (interquartile range [IQR]) age of 1.9 years (IQR, 0.2–6.7 yr), 2651 children (55.2%) were males, and 33 children (0.7%) received ECLS or died within 72 hours. The best-performing initial lactate concentration associated with ECLS or death within 72 hours was 3.5 mmol/L and was observed in 745 of 4806 children (15.5%), including 24 of 33 children requiring ECLS or who died within 72 hours. As a “diagnostic” test, lactate greater than or equal to 3.5 mmol/L had sensitivity (95% CI) of 72.7% (95% CI, 54.5–86.7%), specificity of 84.9% (95% CI, 83.9–85.9%), and area under the receiver-operating characteristics curve of 0.79 (95% CI, 0.71–0.87) for ECLS or death within 72 hours, which are in the acceptable-to-fair category. That is, a 4-hour lactate concentration greater than or equal to 3.5 mmol/L takes the pre- to posttest probability of ECLS/death from 0.7% to 3.2%. Conclusions: In this secondary analysis of the 2021–2023 SENTINEL dataset, we have found that at the time children are hospitalized with suspected community-acquired sepsis, an initial venous lactate greater than or equal to 3.5 mmol/L has an acceptable-to-fair association with subsequent need for ECLS, or death, within 72 hours. Clinicians will need to decide whether such testing on its own is useful in decision-making.

  • Open Access

    Validation of SeptiCyte RAPID to Discriminate Sepsis From Noninfectious Systemic Inflammation in Critically Ill Children

    by Jerry J. Zimmerman, Sainath Raman, Warwick W. Butt, Silvia Cermelli, Roy F. Davis, Elizabeth Y. Killien, Shane George, Kristen S. Gibbons, Adam D. Irwin, Krupa A. Navalkar, et al.

    OBJECTIVES: Biomarkers with adequate precision to rule-in/rule-out sepsis in children represent an unmet need. SeptiCyte RAPID is a point-of-care, U.S. Food and Drug Administration-cleared, host gene expression biomarker test for the determination of sepsis probability (reported in 1 hr as a SeptiScore) using a small-volume peripheral blood sample. We have previously reported on SeptiCyte RAPID performance in adults. Here we report a retrospective, noninterventional clinical validation study of SeptiCyte RAPID, as a sepsis diagnostic adjunct in children. DESIGN, SETTING, AND PATIENTS: Critically ill children ( n = 284), 1 month to 18 years old, admitted to PICUs, with or without suspected or documented infection, but all of whom met criteria for systemic inflammatory response syndrome (SIRS) and were enrolled at multiple clinical sites in the United States and Australia in four separate studies. INTERVENTIONS: None; SeptiCyte RAPID results were not used to guide patient treatment. MEASUREMENTS AND MAIN RESULTS: A combination of clinical adjudication and an independent panel of three physicians (Retrospective Physician Diagnosis [RPD]), blinded to SeptiCyte RAPID results, were used to retrospectively categorize patients into sepsis vs. noninfectious SIRS categories. Diagnostic performance of SeptiCyte RAPID for differentiating sepsis and noninfectious SIRS compared with RPD was measured using area under the curve (AUC), likelihood ratio, and a monotonic increase in probability of sepsis and increasing SeptiScores. Binomial logistic regression analysis was used to integrate clinical parameters in a model based on SeptiCyte RAPID. Higher SeptiScores correlated with higher probability of sepsis. SeptiCyte RAPID AUC for identifying sepsis in children ranged from 0.80 to 0.83. A model additionally integrating lactate, platelet number, mean arterial pressure, Pa co 2 , mechanical ventilation, weight, age, and leukocyte count increased SeptiCyte RAPID performance (AUC, 0.86; 95% CI, 0.85–0.87). CONCLUSIONS: SeptiCyte RAPID demonstrated similar performance characteristics in children to that previously reported for adults. Additional real world effectiveness studies are warranted to determine real-time clinical utility, patient benefits, and health economic impact.

  • Open Access

    REstrictive versus StandarD FlUid Management in Mechanically Ventilated ChildrEn Admitted to PICU: a pilot randomized controlled trial (REDUCE-1)

    by Sainath Raman, Sarfaraz Rahiman, Melanie Kennedy, Eva Kühlwein, Renate Le Marsney, Adrian C. Mattke, Craig A. McBride, Quyen Tu, Prem Venugopal, Jemma Woodgate, et al.

    Objective: Fluid overload in PICU patients is associated with poor outcome. In 2021 we aimed to assess the feasibility of a randomized controlled trial (RCT) of restrictive IV fluid vs. usual IV fluids. Design: Pilot, parallel-arm, open-label RCT (Australian New Zealand Clinical Trials Registry, ACTRN12621001311842). Setting: Two PICUs in Australia and one in Switzerland. Patients: During 2021–2023, we recruited PICU patients aged younger than 18 years who were expected to be invasively ventilated or were already ventilated for greater than 6 hours. Interventions: Patients were randomly allocated to either a restrictive IV fluid strategy or usual care for 48 hours. The restrictive strategy included lower maintenance fluid, smaller fluid boluses and less drug dilution, and earlier diuretics or peritoneal dialysis. Measurements and Main Results: Of 1224 eligible patients, 235 parents were approached and 158 consented (i.e., 67%, one child excluded postrandomization; median [interquartile range, IQR] age was 1.3 yr [IQR 0.3, 7.0]), which meant that the trial did not meet the a priori target recruitment rate. The mean ( sd ) number of patients recruited per month was 6.8 ( sd 3.6). None of 80 patients recruited to the restrictive strategy attained a negative fluid balance greater than10% body weight within 24 hours, compared with 5/77 (6%) in the usual care arm. Median fluid balance at 48 hours postrandomization was 11.1 (IQR –13.7, 40.2) and 8.6 mL/kg (IQR –18.7, 38.8) in the restrictive strategy and usual care, respectively. Median survival free of the PICU for restrictive and usual care was, respectively: 25.0 days (IQR 21.3, 26.0) vs. 24.0 days (IQR 22.1, 26.0). Conclusions: This 2021–2023 pilot RCT shows that the restrictive vs. standard fluid management in mechanically ventilated children (REDUCE-1) protocol would not be feasible if extended to a full RCT, as currently designed. Future approaches may require stricter guidance regarding the intervention, or use of bundled care.

  • A Post‐Extubation Early Feeding Protocol ( PEEF ) in a Tertiary Paediatric Intensive Care Unit: A Quality Improvement Initiative

    by Sora Jung, Sainath Raman, Ian Hughes, Rahul Joshi

    Aim: Recommencing enteral feeding post‐extubation in children is often delayed. This study evaluated a Post‐Extubation Early Feeding (PEEF) protocol on early recommencement of enteral nutrition post‐extubation in a tertiary paediatric intensive care unit (PICU). Methods: The PEEF protocol involved direction to re‐commence enteral nutrition at 50% of the pre‐fasting rate within 1 h of extubation and upgrade to the pre‐extubation feeding rate within 2 h. The PEEF protocol was a quality improvement project implemented at a tertiary PICU and was evaluated through a retrospective analysis. The study included children aged 0–18 years who were admitted to PICU, intubated and subsequently underwent planned extubation pre‐PEEF (November 2019–October 2020) and post‐PEEF (November 2021–October 2022). Results: A total of 795 patients were included in the study, 372 pre‐PEEF and 423 post‐PEEF. Demographic variables and severity of illness variables were similar in the two groups. Post implementation of the PEEF protocol, the median (interquartile range) time to re‐commence enteral nutrition after extubation was 3.2 h (1.9, 4.7) compared to pre‐PEEF, 4.2 h (3.2, 5.5; p = 2.4 × 10 −13 ). Post‐PEEF the median time to reach the pre‐fasting feeding rate was 5 h (2.6, 10.6), compared to 7.3 h (4.1, 13) pre‐PEEF ( p = 0.0005). Conclusions: Implementation of the PEEF protocol reduced the time to resume enteral nutrition and the time to reach pre‐extubation feeding rates although improvement was not consistent with the goals of PEEF. Continuing assessment and education are required to drive outcomes further towards target goals.

  • Open Access

    Can Serum Lactate on Admission to Intensive Care Predict Length of Stay? A Retrospective Analysis of Critically Ill Paediatric Oncology Patients

    by Megan B. Sim, Patricia Gilholm, Endrias Ergetu, Trisha Soosay Raj, Kristen Gibbons, Sainath Raman

    Introduction: Nearly 40% of hospitalised oncology patients are admitted to the paediatric intensive care unit (PICU). Clinicians utilise serum lactate as a biomarker to guide resuscitation and ongoing management of critically ill children. The significance of raised serum lactate remains unknown in oncology patients. Those who require an admission to the PICU have relatively poorer outcomes compared to those only managed on hospital wards, where there may be an increased tendency to apply additional interventions to normalise lactate. We assessed the association between serum lactate and the length of stay in PICU in paediatric oncology patients.Patients and Methods: We conducted a retrospective observational study of patients admitted to the oncology service, who had at least one PICU admission, at a tertiary children's hospital between 2015 and 2020. The outcome was PICU length of stay (LOS). Multilevel regression modelling assessed the association between lactate measured at PICU admission and PICU LOS, controlling for patient demographic and clinical covariates.Results: There were 633 admissions to PICU from 426 children. Of these 633 admissions, 197 (31.1%) had hyperlactatemia (serum lactate ≥ 2 mmol/L) on admission, 229 (36.2%) had normal lactate levels (< 2 mmol/L) and the remaining 207 (32.7%) did not have lactate measured on admission. Of the 426 patients, 292 (68.5%) were diagnosed with solid tumour, 82 (19.2%) hematologic malignancy, and 52 (12.2%) had received a bone marrow transplant (BMT). The median PICU length of stay was 29 h (interquartile range 21, 68). Hyperlactatemia was associated with an average 1.25‐fold (95% CI [1.04, 1.51]) increase in PICU LOS when we assumed that missing lactate indicated absence of hyperlactatemia. Interaction effects revealed that this association was only present in the solid tumour group. In sensitivity analyses including only admissions with measured lactate, this effect was reduced and no longer significant (β 1.20, 95% CI [0.99, 1.46]).Conclusion: After adjusting for clinical and demographic covariates, increased lactate at PICU admission was associated with PICU LOS in paediatric solid tumour patients. While further larger prospective studies are required, serum lactate levels may serve as a predictive biomarker for PICU length of stay in children with solid tumours.


  • Open Access

    Beta-lactam antibiotic administration in critically ill children with sepsis: an international survey of current practice

    by Sainath Raman, Rayna Reddy, Daniela Carla de Souza, Renee Cox, Renate Le Marsney, Karthi Nallasamy, Padmanabhan Ramnarayan, Jason A. Roberts, Luregn J. Schlapbach, Kristen S. Gibbons, et al.

    Objective: To assess current international practices and perceptions regarding beta-lactam antibiotic administration in critically ill children with sepsis. Design, setting, and participants: An electronic survey was distributed among physicians, advanced nurse practitioners and pharmacists working in paediatric intensive care units (PICUs) through PICU research networks from April to August 2024. Main outcome measures: Demographic characteristics, current practices of beta-lactam (meropenem, piperacillin/tazobactam and cefotaxime) administration, reasons for infusion method choices, and perceptions on the efficacy of continuous and extended infusions. Results: Two hundred sixty clinicians responded (236 physicians, 21 pharmacists, 2 advanced nurse practitioners) from 18 countries and 5 continents. Most respondents (88.1%) indicated use of beta-lactams as first-line antibiotics for children with sepsis, with intermittent infusion as the predominant standard practice across the selected beta-lactams (meropenem, 50.2%; piperacillin/tazobactam, 68.5%; and cefotaxime, 82.8%). Among respondents who opted for a continuous or extended infusion on an individual patient basis, 55.0% cited higher severity of illness as the primary reason for choosing this method for meropenem. The majority of respondents (86.5%) agreed there is lack of evidence to embed continuous and/or extended beta-lactam infusions into clinical practice and would recruit (84.6%) to a randomised controlled trial comparing continuous and/or extended and intermittent infusion. Conclusions: This international survey highlights the lack of evidence in beta-lactam administration practices in treating critically ill children with sepsis. There is a clear need and desire for further research through randomised controlled trials to establish optimal beta-lactam infusion methods and investigate their impact on clinical outcomes in the paediatric patient population.


  • Open Access

    The Australian and New Zealand Intensive Care Society Paediatric Study Group (ANZICS PSG): 20 Years of Collaborative Research

    by Kristen S. Vice-Chair Gibbons, John Beca, Carmel Delzoppo, Simon Erickson, Marino Festa, Ben Gelbart, Debbie Long, Kate Masterson, Johnny Millar, Sainath Raman, et al.


  • Open Access

    Implementing paediatric appropriate use criteria for endotracheal suction to reduce complications in mechanically ventilated children with respiratory infections

    by Jessica A. Schults, Karina R. Charles, Jane Harnischfeger, Robert S. Ware, Ruth H. Royle, Joshua M. Byrnes, Debbie A. Long, Amanda J. Ullman, Sainath Raman, Michaela Waak, et al.